Skip to content
Open access · OA via Europe PMC

Simultaneous induction of differentiation and senescence in cardiac fibroblasts by TGF-β1: effects of senotherapeutics drugs.

Espinoza-Perez C, Osorio JM, Vélez R, Ortega Bustos J, Machuca V, Rivas S, Sánchez-Ferrer CF, Peiró C, Vivar R, Díaz-Araya G.

Frontiers in pharmacology · 2026

Abstract

<h4>Introduction</h4>Aging is a major risk factor for cardiovascular diseases (CVD), partly due to the accumulation of senescent cells. Senescence(definition) is characterized by irreversible cell cycle arrest and the acquisition of a senescence associated secretory phenotype (SASP), which promotes inflammation and tissue remodeling, thereby contributing to cardiac dysfunction. Cardiac fibroblasts (CFs), key regulators of cardiac repair, differentiate into myofibroblasts (CMFs) in response to pathological stimuli such as mechanical stiffness and TGF-β1. CMFs secrete abundant extracellular matrix (ECM) proteins, and while their senescence may transiently restrict fibrosis in acute cardiac injury, persistent senescence promotes chronic remodeling through SASP activity. Given that TGF-β1 is a central mediator of CF-to-CMF differentiation and can induce senescence in various cell lines, we investigated whether it simultaneously triggers both processes in neonatal rat CFs, and whether the senotherapeutics Navitoclax and Dasatinib + Quercetin modulate the viability of senescent CMFs.<h4>Methods</h4>CF from neonatal rats were incubated in DMEM-F12 (10% FBS), and treated with TGF-β1 (10 46 ng/mL, 7 days). Proteins were analyzed by Western blot and immunocytochemistry. Cytokines were analyzed by Milliplex. After 7 days cells were treated with senolytics(definition) drugs.<h4>Results</h4>CFs treated with TGF-β1 exhibited senescence markers (p15-p16, p21), increased SA-β-gal activity, and reduced Ki-67 and p-Rb expression. CMFs displayed enhanced secretion of IL-1β, IL-6, IL-5, and IL-10, together with elevated collagen and VCAM-1 levels, indicating a pro-fibrotic and low-grade inflammatory phenotype. Treatment with Navitoclax or Dasatinib + Quercetin decreased cell viability and reduced the proportion of SA-β-gal -positive cells.<h4>Conclusion</h4>TGF-β1 simultaneously promotes CF differentiation into CMFs and induces senescence, resulting in a sustained pro-fibrotic and inflammatory phenotype. Senotherapeutics treatment attenuates senescent CMFs, supporting its potential as a therapeutic strategy to mitigate cardiac fibrosis.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.3389/fphar.2026.1877172
Canonical
link ↗
Fetched
2026-10-07 MST

Cite this

APA
C, E., JM, O., R, V., J, O.B., V, M., S, R., CF, S., C, P., R, V., &amp; G., D. (2026). Simultaneous induction of differentiation and senescence in cardiac fibroblasts by TGF-β1: effects of senotherapeutics drugs. <em>Frontiers in pharmacology</em>. https://doi.org/10.3389/fphar.2026.1877172
Vancouver
C E, JM O, R V, J OB, V M, S R, et al. Simultaneous induction of differentiation and senescence in cardiac fibroblasts by TGF-β1: effects of senotherapeutics drugs. Frontiers in pharmacology. 2026. doi:10.3389/fphar.2026.1877172.
BibTeX
@article{espinozaperez2026Simult, title = {Simultaneous induction of differentiation and senescence in cardiac fibroblasts by TGF-β1: effects of senotherapeutics drugs.}, author = {Espinoza-Perez C and Osorio JM and Vélez R and Ortega Bustos J and Machuca V and Rivas S and Sánchez-Ferrer CF and Peiró C and Vivar R and Díaz-Araya G.}, journal = {Frontiers in pharmacology}, year = {2026}, doi = {10.3389/fphar.2026.1877172}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings